Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Interest Expenses (2023 - 2024)

Oramed Pharmaceuticals (ORMP) has disclosed Interest Expenses for 2 consecutive years, with $261000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Interest Expenses changed N/A year-over-year to $261000.0, compared with a TTM value of $853000.0 through Dec 2024, down 58.12%, and an annual FY2024 reading of $853000.0, down 58.12% over the prior year.
  • Interest Expenses was $261000.0 for Q2 2024 at Oramed Pharmaceuticals, down from $592000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.2 million in Q4 2023 and bottomed at $261000.0 in Q2 2024.